Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat 10 mg vs 5 mg initiation in HFrEF with high systolic blood pressure
ChiCTR2600119938Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vericiguat in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Tolerability success rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2600119938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119938.